Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.42 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 3/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23120954 | 1.00 | MEN1 (0.43) | MEN1KMT2ANPSR1HTTSMN1; SMN2 | |
| SCHEMBL22982626 | 0.94 | PPIA (0.43) | MEN1KMT2ANPSR1HTTSMN1; SMN2 | |
| SCHEMBL19718088 | 0.94 | MEN1 (0.47) | MEN1KMT2ANPSR1HTTSMN1; SMN2 | |
| SCHEMBL13738046 | 0.93 | SYK (0.44) | MEN1KMT2ANPSR1HTTSMN1; SMN2 | |
| SCHEMBL24940830 | 0.92 | MEN1 (0.43) | MEN1KMT2ASYK | |
| SCHEMBL23121006 | 0.91 | HTT (0.44) | MEN1KMT2ANPSR1HTTSMN1; SMN2 | |
| SCHEMBL15774429 | 0.91 | CNR2 (0.43) | MEN1KMT2ANPSR1HTTSMN1; SMN2 | |
| SCHEMBL8569029 | 0.91 | PIK3R1 (0.45) | MEN1KMT2ANPSR1HTTSMN1; SMN2 | |
| SCHEMBL15788896 | 0.89 | CNR2 (0.51) | MEN1KMT2ANPSR1HTTSMN1; SMN2 | |
| SCHEMBL15775037 | 0.87 | TMEM97 (0.41) | MEN1KMT2ANPSR1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4013756-B1 | MLL1 INHIBITORS AND ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2024-05-08 | — | — | EP | disclosed |
| US-20220380371-A1 | MLL1 INHIBITORS AND ANTI-CANCER AGENTS | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. (CN) | 2022-12-01 | — | — | US | disclosed |
| EP-4013756-A1 | MLL1 INHIBITORS AND ANTI-CANCER AGENTS | Novartis AG (CH) | 2022-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380371-A1 | MLL1 INHIBITORS AND ANTI-CANCER AGENTS | MLLT1, BMI1, DOT1L | MEN1 539/4885KMT2A 10/4885NPSR1 4710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.